HPLC

Unilumin and Huawei Jointly Unveiled the Smart Pole Site Joint Solution at MWC 2024

Retrieved on: 
Friday, March 1, 2024
Cloud, ICT, Multimedia, ONU, Internet of things, HPLC, Intelligence, Communication, City, Optical line termination, Huawei, IP, Network interface device, O&M, Speech, LED

BARCELONA, Spain, Feb. 29, 2024 /PRNewswire/ -- At MWC 2024, a premier annual event in the international telecommunications industry, Unilumin Group Co., Ltd. (Unilumin), in collaboration with Huawei, unveiled the Smart Pole Site Joint Solution to accelerate smart city transformation through ICT.

Key Points: 
  • BARCELONA, Spain, Feb. 29, 2024 /PRNewswire/ -- At MWC 2024, a premier annual event in the international telecommunications industry, Unilumin Group Co., Ltd. (Unilumin), in collaboration with Huawei, unveiled the Smart Pole Site Joint Solution to accelerate smart city transformation through ICT.
  • Larry Li, Eric He – CEO of Digital Site BU, Huawei, and Cui Dongfeng – Solution Director of Digital Site, Huawei, together released the Smart Pole Site Joint Solution.
  • Based on Huawei's smart pole site portfolio solution, this solution is designed to promote the construction of smart cities that emphasize secure, sustainable, intelligent, and efficient city operations, improved city governance, and comprehensive city sensing management.
  • The Smart Pole Site Joint Solution not only signifies a new milestone in the construction of smart cities but also heralds a more efficient and intelligent transformation in urban governance.

Huawei Launches Intelligent Distribution Solution (IDS) to Accelerate Electric Power Intelligence

Retrieved on: 
Wednesday, February 28, 2024
Acquisition, Mobile, ECU, HPLC, Communication, Perception, IDS, Ecosystem, Speech, Mobile phone

Huawei launched its Intelligent Distribution Solution (IDS) during the summit themed "Leading Infrastructure to Accelerate Electric Power Intelligence".

Key Points: 
  • Huawei launched its Intelligent Distribution Solution (IDS) during the summit themed "Leading Infrastructure to Accelerate Electric Power Intelligence".
  • David Sun, Vice President of Huawei and CEO of Electric Power Digitalization BU, Huawei, delivered a keynote speech and launched the IDS.
  • Huawei collaborated with ecosystem partners to develop the solution, which addresses high line loss, poor reliability, and heavy pressure on new energy load management.
  • It enables electric power enterprises to transition from single-point digitalization to architecture-supported, open, evolvable, and systematic digitalization, utilizing various key technologies based on a cloud-pipe-edge-pipe-device architecture.

MWC2024 | Huawei and Unilumin Co-Launch the Smart Pole Site Joint Solution

Retrieved on: 
Wednesday, February 28, 2024
Cloud, ICT, Power-line communication, O&M, ONU, Internet of things, HPLC, Communication, ESight, City, Optical line termination, Huawei, IP, Network interface device, Speech

BARCELONA, Spain, Feb. 28, 2024 /PRNewswire/ -- At MWC Barcelona 2024, Huawei and Unilumin Group Co., Ltd. (Unilumin) co-launched the Smart Pole Site Joint Solution to accelerate smart city transformation through ICT.

Key Points: 
  • BARCELONA, Spain, Feb. 28, 2024 /PRNewswire/ -- At MWC Barcelona 2024, Huawei and Unilumin Group Co., Ltd. (Unilumin) co-launched the Smart Pole Site Joint Solution to accelerate smart city transformation through ICT.
  • Dr. Larry Li, Vice President of Unilumin, delivered the opening speech, titled Multiple Integration, Group Intelligence Collaboration, to Create Smart City Neuron.
  • Larry Li, Eric He – CEO of Digital Site BU, Huawei, and Cui Dongfeng – Solution Director of Digital Site, Huawei, together released the Smart Pole Site Joint Solution.
  • Based on Huawei's smart pole site portfolio solution, this solution is designed to promote the construction of smart cities that highlight secure, sustainable, intelligent, and efficient city operations, improved city governance, and comprehensive city sensing management.

Waters Announces Seamless HPLC/UPLC Data Bridge for Light Scattering, Integrating Essential Instruments for Large Molecule Characterization

Retrieved on: 
Monday, February 26, 2024
CONNECT, Wyatt Technology Corporation, Acquisition, SAN, Drug development, Data collection, HPLC, QA/QC, WAT, Waters Corporation, UV, Risk, MALS, Peptide, Protein, Wyatt (surname), Software, Fine chemical

SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Pittcon 2024 – Waters Corporation (NYSE:WAT) announced HPLC CONNECT software, an all-in-one software platform that enables full digital synchronization between Waters high- and ultra-performance liquid chromatography (HPLC/UPLC) systems and multi-angle light-scattering instruments (MALS) from its Wyatt Technology™ portfolio. The software delivers ease-of-use, greater efficiency, and higher confidence for scientists performing size exclusion chromatography and MALS (SEC-MALS) analyses for complex and critical biopharmaceutical innovations, including antibody drug conjugates, other complex protein conjugates, and gene therapies.

Key Points: 
  • Waters now enables seamless connectivity between its liquid chromatography (LC) systems and multi-angle light-scattering instruments (MALS) for improved ease-of-use, efficiency, and data confidence in characterizing large molecules.
  • HPLC CONNECT™ software accelerates precise characterization of complex molecules for the development of biologic drugs, including antibody drug conjugates, other complex protein conjugates, and gene therapies.
  • HPLC CONNECT software greatly simplifies characterization of large molecules – a critical step in developing biologics.
  • Waters HPLC CONNECT software removes a significant amount of labor, reduces risk of human error, and delivers unmatched confidence in the data generated during analysis."

Waters Announces Seamless HPLC/UPLC Data Bridge for Light Scattering, Integrating Essential Instruments for Large Molecule Characterization

Retrieved on: 
Monday, February 26, 2024
CONNECT, Wyatt Technology Corporation, Acquisition, SAN, Drug development, Data collection, HPLC, QA/QC, WAT, Waters Corporation, UV, Risk, MALS, Peptide, Protein, Wyatt (surname), Software, Fine chemical

SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Pittcon 2024 – Waters Corporation (NYSE:WAT) announced HPLC CONNECT software, an all-in-one software platform that enables full digital synchronization between Waters high- and ultra-performance liquid chromatography (HPLC/UPLC) systems and multi-angle light-scattering instruments (MALS) from its Wyatt Technology™ portfolio. The software delivers ease-of-use, greater efficiency, and higher confidence for scientists performing size exclusion chromatography and MALS (SEC-MALS) analyses for complex and critical biopharmaceutical innovations, including antibody drug conjugates, other complex protein conjugates, and gene therapies.

Key Points: 
  • Waters now enables seamless connectivity between its liquid chromatography (LC) systems and multi-angle light-scattering instruments (MALS) for improved ease-of-use, efficiency, and data confidence in characterizing large molecules.
  • HPLC CONNECT™ software accelerates precise characterization of complex molecules for the development of biologic drugs, including antibody drug conjugates, other complex protein conjugates, and gene therapies.
  • Waters HPLC CONNECT software removes a significant amount of labor, reduces risk of human error, and delivers unmatched confidence in the data generated during analysis."
  • HPLC CONNECT software supports select Waters™ LC systems including the ACQUITY™ Premier, Arc Premier, and Arc Systems.

Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video

Retrieved on: 
Monday, February 12, 2024
Health Canada, MAPS, FDA, Food, FRA, HPLC, GMP, PDUFA, MDMA, Safety, Therapy, Lycus, PTSD, NDA, Chromatography, Pharmaceutical industry

Additionally, Optimi is pleased to unveil a six-minute video showcasing its end-to-end GMP MDMA encapsulation and production process.

Key Points: 
  • Additionally, Optimi is pleased to unveil a six-minute video showcasing its end-to-end GMP MDMA encapsulation and production process.
  • The FDA's priority review designation underscores the significance of this potential breakthrough in providing effective treatment options for those impacted by this debilitating condition.
  • Bill Ciprick, CEO of Optimi Health, stated, "We commend Lykos Therapeutics and MAPS founder, Rick Doblin, for their unwavering dedication to advancing innovative therapies for PTSD.
  • Stevens stated, "The ability to showcase our GMP MDMA production process is a testament to our commitment to excellence and transparency.

Study of First Affordable and Rapid Test for Beta Thalassemia Performs at 99% Accuracy in Diagnosing the Blood Disorder

Retrieved on: 
Monday, February 5, 2024
Medicine, Survival, Beta thalassemia, Trial of the century, MD, Child, Diagnosis, Incidence, Marriage, Gazelle, Biosensor, Patient, Disease, European Journal, Hematology, HPLC, Pharmaceutical industry

This study concluded that Gazelle provides, for the first time, an affordable and rapid solution for identifying beta-thal at point of care.

Key Points: 
  • This study concluded that Gazelle provides, for the first time, an affordable and rapid solution for identifying beta-thal at point of care.
  • The ability to test accurately and rapidly (results are available in 8 minutes) as demonstrated in this study suggests that Gazelle is suitable for large-scale testing of beta-thal at point of care.
  • Beta thalassemia is an inherited blood disorder.
  • A study published in the European Journal of Hematology has shown, however, that incidence rates decrease in areas with screening and education programs.

Branded Legacy, Inc. Unveils Major Equipment Acquisition Raising Total Assets to $3,787,215.00

Retrieved on: 
Tuesday, January 30, 2024
Environment, High-performance liquid chromatography, Acquisition, Laboratory, Research, HPLC, Negotiation, BLEG, Gas chromatography, Incubator

MELBOURNE, Fla., Jan. 30, 2024 /PRNewswire/ -- Branded Legacy, Inc. (OTC.PK: BLEG), a leading innovator in research, development, and production, announces that it has increased its assets to $3,787,215.00, which is a 1,412% increase as compared to the end of Q3. The Company's recently acquired Laboratory and packing equipment greatly bolsters its research and development, product production and packaging operations.

Key Points: 
  • The Company's recently acquired Laboratory and packing equipment greatly bolsters its research and development, product production and packaging operations.
  • The Company recently expanded its capabilities with the acquisition of state-of-the-art equipment valued at $252,900.00 at a cost of $106,500.00 while incurring no additional debt.
  • The total investment of $106,500.00 demonstrates BLEG's commitment to advancing its capabilities and staying at the forefront of technological innovation.
  • In addition to the equipment acquisition, BLEG acknowledges that its current facilities are reaching capacity.

Joint research collaboration with Chemical Microscopy, LLC featured in the "Improving Product Quality & Material Understanding" special issue of Pharmaceutical Research

Retrieved on: 
Friday, January 26, 2024
Quotient, Powder, Pharmacy, Medication, Compound, PLM, Caffeine, RAM, HPLC, Therapy, Research

WEST LAFAYETTE, Ind., Jan. 26, 2024 /PRNewswire-PRWeb/ -- Research for low-dose therapeutics is a growing trend as promising new highly potent therapeutic agents are developed. Compounds deemed "highly potent" in pharmaceutical pipelines today describe nearly half of all market approved products and half of the small molecules currently advancing in clinical studies. Therefore, understanding how to achieve blend and content uniformity during powder mixing steps is critical in the design of robust low-dose solid dosage drug products, and yet remains a challenge for conventional blending technologies to reliably achieve this essential critical quality attribute.

Key Points: 
  • Original research article advances understanding of resonant acoustic mixing technology for rapidly achieving uniformity in ultra low-dose powder blends with challenging particle morphologies.
  • WEST LAFAYETTE, Ind., Jan. 26, 2024 /PRNewswire-PRWeb/ -- Research for low-dose therapeutics is a growing trend as promising new highly potent therapeutic agents are developed.
  • Compounds deemed "highly potent" in pharmaceutical pipelines today describe nearly half of all market approved products and half of the small molecules currently advancing in clinical studies.
  • This work is published in a recent special issue of Pharmaceutical Research dedicated to Professor Kenneth R. Morris.

Hi-Tech Pharmaceuticals AshwaPure® Brand Ashwagandha Increases Capacity of Production Due to Success of its Initial Launch!

Retrieved on: 
Thursday, January 4, 2024
Online, Marketing, Withanolide, Research, Gold standard, Medicine, Anxiety, Growth, HPLC, Memory, Pharmaceutical industry

Thanks to its ability to support both the mind and the body, ashwagandha is one of Ayruveda's most prized rejuvenating herbs.

Key Points: 
  • Thanks to its ability to support both the mind and the body, ashwagandha is one of Ayruveda's most prized rejuvenating herbs.
  • AshwaPure® is an extract developed in-house by Hi-Tech Pharmaceuticals and had custom produced for our company.
  • First and foremost, Hi-Tech AshwaPure® has a very high level of withanolides on the market at 5% by HPLC.
  • Unlike some other herbs that are sold, ashwagandha is not seasonable, as we all experience it in today's hectic world.